PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Gauges a company's financial stability and solvency. Value investors pay close attention to leverage and liquidity risk, ensuring the company has enough cushion to withstand downturns without impairing shareholder value.
0.13
D/E ratio exceeding 1.5x Healthcare median of 0.04. Howard Marks would check for debt covenant compliance and refinancing risks.
2.00
Net debt aligned with Healthcare median of 1.92. David Dodd would verify if industry standard leverage is appropriate given business cyclicality.
No Data
No Data available this quarter, please select a different quarter.
2.63
Current ratio near Healthcare median of 2.57. David Dodd would examine if industry-standard liquidity is appropriate given business model.
No Data
No Data available this quarter, please select a different quarter.